Aravive (STU:VE11) Treasury Stock : €0.00 Mil (As of Sep. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Aravive Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Aravive's treasury stock for the quarter that ended in Sep. 2023 was €0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Aravive Treasury Stock Historical Data

The historical data trend for Aravive's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aravive Treasury Stock Chart

Aravive Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Treasury Stock

Get a 7-Day Free Trial

Aravive Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Treasury Stock	Get a 7-Day Free Trial															-	-	-	-	-

Aravive Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Aravive Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (STU:VE11) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

3730 Kirby Drive, River Oaks Tower, Suite 1200, Houston, TX, USA, 77098

Website

https://www.aravive.com

Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.

Aravive Headlines

No Headlines